Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 05MANILA5447, PHARMACEUTICAL PATENT PROTECTION ON THE CHOPPING

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05MANILA5447.
Reference ID Created Released Classification Origin
05MANILA5447 2005-11-22 03:12 2011-08-25 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Manila
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 02 MANILA 005447 
 
SIPDIS 
 
Sensitive 
 
STATE FOR EAP/MTS 
STATE PASS TO USTR FOR BWEISEL AND DKATZ 
STATE PASS TO USAID FOR CDOWNEY 
USDOC FOR 4430/ITA/MAC/DBISBEE 
USDOC PASS TO USPTO FOR PFOWLER, KHAUDA 
 
E.O. 12958: N/A 
TAGS: ECON ETRD KIPR BEXP RP
SUBJECT:  PHARMACEUTICAL PATENT PROTECTION ON THE CHOPPING 
BLOCK 
 
Sensitive but Unclassified - Not for Internet - Protect 
Accordingly. 
 
------- 
SUMMARY 
------- 
 
1.  (SBU)  Senator Manuel Roxas, Chairman of the Senate 
Committee on Economic Affairs and the Committee on Trade and 
Commerce, introduced a bill last month proposing amendments 
to the RP's Intellectual Property Code (IP) that could 
significantly weaken intellectual property rights protection 
for pharmaceutical products.  The bill would further 
liberalize the compulsory licensing provision, allow the 
"early use" of patented drugs by potential generic 
manufacturers, and expand parallel importation.  Committee 
hearings on SB2139 are scheduled to start this week. 
Embassy has written to Roxas expressing our concern and are 
trying to meet with him at the earliest opportunity.  End 
Summary. 
 
------------------------------------------- 
SENATE BILL WEAKENS DRUG PATENT PROTECTIONS 
------------------------------------------- 
 
2.  (U)  Senator Manuel ("Mar") Roxas, Chairman of the 
Senate Committee on Economic Affairs and the Committee on 
Trade and Commerce, introduced a bill last month (SB2139) to 
amend the Intellectual Property Code (IP) of the 
Philippines.  Based on conversations with GRP officials and 
industry representatives, Embassy understands that the bill 
proposes three major changes that could significantly weaken 
intellectual property rights protection for pharmaceutical 
products.   First, it would liberalize compulsory licensing 
by immediately allowing exceptions when drugs or medicines 
are to "protect public health."  Current compulsory 
licensing provisions involve a lengthy bureaucratic process. 
Since the law's inception in 1998, only four cases have been 
filed. 
 
3.  (U)  Second, the bill includes an "early use" provision 
that would allow the experimentation, production and 
registration of a patented drug and its data before the 
expiration of the patent.  This would permit manufacturers 
to make and sell the drug as a generic immediately after 
patent expiration.  Current law provides patent protection 
for a product from the date of patent approval in the 
Philippines, provided that the patent application is filed 
within one year of the product's introduction to the world 
market.  The Roxas proposal would nullify any advantage to 
filing a local patent in the Philippines and reduce the 
overall period of patent protection. 
 
4.  (U)  Third, the Roxas bill would allow parallel 
importation of drugs and medicine by the government, again 
under the umbrella of "public health," upon application to 
the Intellectual Property Office (IPO), regardless of 
whether the imported product is protected by a local patent. 
Currently, parallel imports are not allowed for products 
under patent protection in the Philippines.  The Roxas 
proposal, therefore, expands parallel imports by eliminating 
local patent protection on imported medicines.  In addition, 
the bill prohibits the ability of a rights holder to apply 
for an additional patent for a "new use" discovered for a 
drug with an existing patent. 
 
------------------------------------------ 
DIVERGENT VIEWS ON PATENT PROTECTION NEEDS 
------------------------------------------ 
 
5.  (SBU)  In mid-October, the GRP co-sponsored a forum on 
public health with the Philippine Chamber of the 
Pharmaceutical Industry (PCPI), a local industry advocacy 
group composed of Philippine generic manufacturers, to 
"examine flexibilities" in the Trade-Related Aspects of 
Intellectual Property Rights Agreement (TRIPS) with respect 
to patents, including compulsory licensing, early use 
provisions, and allowances for parallel importation. 
Although Embassy was not invited to the event, the 
Pharmaceutical and Healthcare Association of the Philippines 
(PHAP), an industry association with members holding U.S. 
patent rights, said the forum was attended by pharmaceutical 
industry representatives, officials from the Department of 
Trade and Industry, Department of Health and the Bureau of 
Food and Drugs, the Chair of the House Committee on Trade 
and Industry, and the Vice-Chair of the House Committee on 
Health. 
6.  (SBU) Ireneo Galicia, Deputy Director General at the 
Intellectual Property Office, told Econoff that the Roxas 
bill was "mentioned" at the forum and a "brief description 
of the salient points of the bill" was provided.  According 
to Galicia, Senator Roxas sees patents as the main cause 
behind high medicine costs.  However, one of the forum 
briefing papers, submitted by IPO itself, expressed "a 
growing concern that the TRIPS standards for intellectual 
property rights may have negative implications with regard 
to affordability and access to medicines, especially in the 
Philippines."  Galicia commented that Roxas does not 
necessarily take into account other factors such as 
production prices.  Galicia noted that the IPO tried to 
"disabuse" attendees of the notion that patents are the only 
problem.  He said the forum helped Roxas understand there 
are other ways to reduce medicine prices.  Galicia still 
expects committee hearings to move forward on the Roxas 
bill, however. 
 
7.  (SBU) Representatives from Pfizer and from PHAP had a 
completely different assessment of the forum, expressing 
dissatisfaction with the way it was organized and a general 
feeling that the cards were stacked against patent holding 
pharmaceutical companies.  PHAP indicated that industry 
representatives, aside from those of the local PCPI, were 
given very little time to speak and felt that their views 
were not heard.  Pfizer expressed similar concerns, noting 
that it seemed like the forum was organized so as to garner 
support for the Roxas bill rather than to provide a balanced 
discussion of alternative ways to reduce medicine costs. 
 
8.  (SBU)  Overall, Galicia said the forum highlighted the 
need for the IPO to revisit pertinent rules and regulations, 
as well as business processes, in order to improve overall 
efficiency and effectiveness.  Specifically, IPO needs to 
reexamine whether "issued patents are of good quality" 
(meaning that IPO is issuing patents appropriately) and 
whether rules are being applied uniformly.  In the 
meanwhile, SB2139 will move forward to committee hearings 
this week.  Rumor has it that Representative Ferjenel Biron, 
Vice-Chair of the House Committee on Health, intends to file 
a counter-bill in the House that closely models the Senate 
version. 
 
9.  (U)  Embassy has written to Senator Roxas expressing USG 
concern with the legislation and Econ Counselor has 
requested a meeting with him to underscore these concerns. 
 
------- 
COMMENT 
------- 
 
10.  (SBU)  The Roxas bill is especially troubling to U.S. 
pharmaceutical rights holders who are trying to retain their 
market share and profitability in the Philippines.  While 
the bill taps into more flexible provisions in TRIPS, it may 
not offer enough protection for drug makers.  Passage of the 
bill would not reflect well on the Philippines' efforts to 
improve IPR and be removed from USTR's Special 301 Priority 
Watch List, following its out-of-cycle review this January. 
U.S. pharmaceutical patent holders, represented by PHAP, may 
defuse concerns about the high drug costs and the potential 
for an avian flu pandemic by focusing on alternate ways to 
reduce the cost of medicine, and support information 
exchange and planning to address any potential pandemic. 
 
JONES